Piqray and Skin toxicity - a phase IV clinical study of FDA data

Summary:

Skin toxicity is reported as a side effect among people who take Piqray (alpelisib), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Fulvestrant, and have Breast cancer metastatic.

The phase IV clinical study analyzes which people have Skin toxicity when taking Piqray. It is created by eHealthMe based on reports of 7,290 people who have side effects when taking Piqray from the FDA, and is updated regularly.

What is Piqray?

Piqray has active ingredients of alpelisib. eHealthMe is studying from 7,290 Piqray users. Check the latest studies of Piqray.

What is Skin toxicity?

Skin toxicity (skin damage due to toxin/poison) is found to be associated with 269 drugs and 376 conditions by eHealthMe. Check the latest studies of Skin toxicity.

On Jul, 20, 2026

7,290 people reported to have side effects when taking Piqray.
Among them, 20 people (0.27%) have Skin toxicity.

Among these 20 people:

How long have people been on Piqray when they have Skin toxicity? *

What is the gender of people who have Skin toxicity when taking Piqray? *

female: 100 %
male: 0.0 %

What is the age of people who have Skin toxicity when taking Piqray? *

What are other drugs people take besides Piqray? *

What are other side effects people have besides Skin toxicity? *

Rashes (redness): 11 people, 55.00%
Fatigue (feeling of tiredness): 4 people, 20.00%
Hyperglycemia (high blood sugar): 4 people, 20.00%
Hypersensitivity: 3 people, 15.00%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 3 people, 15.00%
Skin Hyperpigmentation (disorders affect the colour of your skin): 3 people, 15.00%
Blood Glucose Increased: 3 people, 15.00%
Pain In Extremity: 3 people, 15.00%
Oedema (fluid collection in tissue): 3 people, 15.00%
Fever: 3 people, 15.00%

What are the existing conditions these people have? *

Breast Cancer Metastatic: 9 people, 45.00%
Breast Cancer: 4 people, 20.00%
Vaginal Cancer Recurrent: 2 people, 10.00%
Metastases To Bone (cancer spreads to bone): 2 people, 10.00%
Pain: 1 person, 5.00%
Ovarian Cancer (cancer of ovary): 1 person, 5.00%
High Blood Pressure: 1 person, 5.00%
High Blood Cholesterol: 1 person, 5.00%
Chronic Thyroiditis (long lasting inflammation of thyroid gland): 1 person, 5.00%

* Approximation only. Some reports may have incomplete information.

Do you take Piqray and have Skin toxicity?

- Check whether Skin toxicity is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Piqray:

Piqray (7,290 reports)

Skin toxicity treatments and more:

Skin toxicity (5,295 reports)

Browse all side effects of Piqray:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Skin toxicity:

Skin toxicity (270 drugs)

Browse all the conditions that are associated with Skin toxicity:

Skin toxicity (376 conditions)

Related publications that referenced our studies

Kim DJ, Lee SC, Park GS, Kim GJ, Hwang WT, Lee CS, Lee MH, Hahn DH, Koh HC, "Amiodarone Induced Multiorgan Toxicity in a Patient of Hypertrophic Cardiomyopathy With Atrial Fibrillation", Journal of the Korean Geriatrics Society, 2013 Dec .
Kim DJ, Lee SC, Park GS, Kim GJ, Hwang WT, Lee CS, Lee MH, Hahn DH, Koh HC, "Amiodarone Induced Multiorgan Toxicity in a Patient of Hypertrophic Cardiomyopathy With Atrial Fibrillation", Journal of the Korean Geriatrics Society, 2013 Dec .

How the study uses the data?

The study uses data from the FDA. It is based on alpelisib (the active ingredients of Piqray) and Piqray (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.